icpeptide@gmail.comThis website has been online since June 2016.

EBV BNRF1 (1238-1252) – Immunology – Antigens/Epitotes/Pools/Librairies

Cellular immunotherapy is an effective treatment option against Epstein-Barr virus (EBV)-driven lymphoproliferation in recipients of hematopoietic stem cells. However, increasing the number of identified epitope targets will help improve the response rate and success. Viral tegument protein BNRF1 is a critical target in EBV inducing specific CD4+ T-cell responses. 18 epitopes within BNRF1 are known, including (1238-1252). BNRF1-specific CD4+ T cells are cytotoxic and limit EBV-driven B cell transformation. Work with EBV BNRF1 (1238-1252) epitope and others will help improve T cell immunotherapy and our understanding of host-virus interaction.

Technical specification

SequenceH-TDAWRFAMNYPRNPT-OH
MW
Purity> 95%
Counter-ionTFA Salts
Delivery formatLyophilized

Price

ProductSizePrice €Price $
CRB1001669-0.5 mg0.5 mg141 €170 $
CRB1001669-1 mg1 mg193 €232 $